AI-Designed Drug Rentosertib Shifts Six Aging Clocks in Phase IIa Trial
AIFlow_ML · x · 2026-09-10
- Rentosertib, an AI-designed drug by Insilico Medicine originally developed for idiopathic pulmonary fibrosis (IPF), showed anti-aging effects in a Phase IIa trial.
- Six proteomic "aging clocks" applied to blood samples from 42 participants all detected reductions in predicted biological age, while the placebo group showed little change or slight increases; effects were most pronounced around week 4.
- AI played a dual role: identifying TNIK, an enzyme linked to both fibrosis and aging pathways, and generating/optimizing the inhibiting molecule.
- The study was authored by Insilico with collaborators from Harvard, Stanford, the Broad Institute, RWTH Aachen, Peking University, and Westlake University.
Related event: Insilico's AI-designed drug appears to slow biological aging(2 posts)→
More from Research
- Minqi Jiang: AI won't replace mathematicians, it's a new kind of telescope — MinqiJiang · 2026-09-10
- Recirculation paper: leaking late-layer activations boosts frozen Gemma3's GSM8k accuracy by 21% — s_scardapane · 2026-09-10
- Paper unveils preliminary Agent Swarm RL recipe; V4.1 teams hit 30% on ProgramBench — inductionheads · 2026-09-10
- OpenAegis doubles security-agent pass rate to 58.1% via CyberFactory trajectories — jiqizhixin · 2026-09-10
- Semantic bottleneck enables non-invasive sentence decoding from MEG signals — pnpl · 2026-09-10
- Gen2Balance at ECCV 2026: generative videos fill long-tailed action datasets to reach SOTA — dimadamen · 2026-09-10